BRIEF: Qyuns Therapeutics secures CSRC approval for full H-share circulation
Biopharmaceutical company Qyuns Therapeutics Co. Ltd. (2509.HK) announced on Tuesday that the China Securities Regulatory Commission (CSRC) has approved its plan to convert 17.32 million of its domestic shares into…
